deltatrials
Completed PHASE4 INTERVENTIONAL 1-arm NCT03369665

Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)

A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS)

Sponsor: Merck KGaA, Darmstadt, Germany

Interventions Mavenclad®
Updated 24 times since 2017 Last updated: Nov 9, 2022 Started: Jun 20, 2018 Primary completion: Nov 12, 2021 Completion: Nov 12, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03369665, this PHASE4 trial focuses on Multiple Sclerosis and remains completed. Sponsored by Merck KGaA, Darmstadt, Germany, it has been updated 24 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~Oct 2023 · 20 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

24 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE4

  5. Feb 2022 — Oct 2023 [monthly]

    Completed PHASE4

    Status: Active Not RecruitingCompleted

Show 19 earlier versions
  1. Oct 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE4

  2. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE4

  3. Mar 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE4

  4. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE4

  5. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE4

  6. Feb 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE4

  7. Nov 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE4

  8. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE4

    Status: RecruitingActive Not Recruiting

  9. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE4

  10. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE4

  11. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE4

  12. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE4

  13. Jan 2019 — Apr 2019 [monthly]

    Recruiting PHASE4

  14. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE4

  15. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE4

    Status: Not Yet RecruitingRecruiting

  16. Jul 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE4

  17. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE4

  18. Mar 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE4

  19. Dec 2017 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck KGaA, Darmstadt, Germany
Data source: Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .